Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|21|12|1391-1404

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.12, 2014-04, pp. : 1391-1404

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection

By Herbst D Alan   Reddy K Rajender  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite

A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ravidasvir

By  

Current Drug Discovery Technologies, Vol. 15, Iss. 1, 2018-04 ,pp. : 24-31

Bentham Science Publishers

Access to resources Recommend Favorite

A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir

By  

Current Medicinal Chemistry, Vol. 20, Iss. 30, 2013-10 ,pp. : 3733-3742

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein

By  

Mini Reviews in Medicinal Chemistry, Vol. 15, Iss. 7, 2015-06 ,pp. : 553-581

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Discovery and Development of Promising Therapeutics against Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase

By  

Mini Reviews in Medicinal Chemistry, Vol. 5, Iss. 12, 2005-12 ,pp. : 1103-1112

Bentham Science Publishers

Access to resources Recommend Favorite